Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance

阻断素抑制线粒体 ROS 可导致胶质母细胞瘤进展和治疗耐药性

阅读:10
作者:Haohao Huang #, Songyang Zhang #, Yuanyuan Li #, Zhaodan Liu, Lanjuan Mi, Yan Cai, Xinzheng Wang, Lishu Chen, Haowen Ran, Dake Xiao, Fangye Li, Jiaqi Wu, Tingting Li, Qiuying Han, Liang Chen, Xin Pan, Huiyan Li, Tao Li, Kun He, Ailing Li, Xuemin Zhang, Tao Zhou, Qing Xia, Jianghong Man

Abstract

Low levels of reactive oxygen species (ROS) are crucial for maintaining cancer stem cells (CSCs) and their ability to resist therapy, but the ROS regulatory mechanisms in CSCs remains to be explored. Here, we discover that prohibitin (PHB) specifically regulates mitochondrial ROS production in glioma stem-like cells (GSCs) and facilitates GSC radiotherapeutic resistance. We find that PHB is upregulated in GSCs and is associated with malignant gliomas progression and poor prognosis. PHB binds to peroxiredoxin3 (PRDX3), a mitochondrion-specific peroxidase, and stabilizes PRDX3 protein through the ubiquitin-proteasome pathway. Knockout of PHB dramatically elevates ROS levels, thereby inhibiting GSC self-renewal. Importantly, deletion or pharmacological inhibition of PHB potently slows tumor growth and sensitizes tumors to radiotherapy, thus providing significant survival benefits in GSC-derived orthotopic tumors and glioblastoma patient-derived xenografts. These results reveal a selective role of PHB in mitochondrial ROS regulation in GSCs and suggest that targeting PHB improves radiotherapeutic efficacy in glioblastoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。